Cognition Therapeutics enters $40M ATM equity offering with Cantor and B. Riley

COGNITION THERAPEUTICS INC

Entered Controlled Equity Offering Sales Agreement with Cantor Fitzgerald and B. Riley Securities.
May sell up to $40 million of common stock in at-the-market offerings from time to time.
Agents will receive a commission of 3.0% of gross proceeds from sales.
Offering is subject to effectiveness of a registration statement on Form S-3 filed same day.
Company is not obligated to make any sales under the agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

COGNITION THERAPEUTICS INC entered into Sales Agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. valued at up to $40 million (effective 2022-12-23).

Action: entry
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co. and B. Riley Securities, Inc.
Value: up to $40 million
Effective: 2022-12-23

Exact text from the filing

On December 23, 2022, Cognition Therapeutics, Inc. (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (each, an “Agent”, and together the “Agents”), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $40 million through or to the Agents.

View on SEC.gov

Browse all material agreements →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-22-129912

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.